### IN THIS ISSUE
Highlighted research articles

**REVIEW**

**Antiangiogenic Therapies: Going beyond Their Limits**
L. Moserle, G. Jiménez-Valerio, and O. Casanovas

**RESEARCH BRIEFS**

**mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1**

Précis: mTORC inhibitors decrease MCL-1 translation and cooperate with BCL-2/BCL-XL inhibitors to induce apoptosis and growth arrest in KRAS- and BRAF-mutant colorectal cancer. See commentary, p. 19

---

**Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity**

Précis: Repression of specific miRNAs antagonizes the tumor-suppressive activity of HIF1α in ccRCC tumors by augmenting expression of the oncoprotein HIF2α. See commentary, p. 19

---

**MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition**

Précis: Whole-exome and transcriptome sequencing of dabrafenib- and trametinib-resistant melanomas identifies putative mechanisms of acquired resistance to combined RAF/MEK inhibition. See commentary, p. 19

---

### NEWS IN BRIEF
Important news stories affecting the community

**Q&A: Mitchell Zeller on the FDA and Tobacco**
M. Russo, F. Di Nicolantonio, and A. Bardelli

See article, p. 42

**The Science of Tobacco Addiction and Cessation**
H. Moch and M. Lukamowicz-Rajska

See article, p. 53

---

### NEWS IN DEPTH
Selected highlights of recent articles of exceptional significance from the cancer literature

**In The Spotlight**

**Climbing RAS, the Everest of Oncogenes**
M. Russo, F. Di Nicolantonio, and A. Bardelli

See article, p. 19

**miR-30c-2-3p and miR-30a-3p: New Pieces of the Jigsaw Puzzle in HIF2α Regulation**
H. Moch and M. Lukamowicz-Rajska

See article, p. 22

**Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis**
R.A. Brekken

See article, p. 110

---

**In Focus**

**Towards a Unified Model of RAF Inhibitor Resistance**
D.B. Solit and N. Rosen

See articles, p. 61, p. 69, p. 80, p. 94

---

For more News and Research Watch, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
Using data from a high-throughput drug screen, Faber and colleagues found that AZD8055, an inhibitor of mTOR complexes 1 and 2 (TORC1/2), cooperated with the BCL-2/BCL-XL inhibitor ABT-263 to induce cell-cycle arrest and apoptosis specifically in KRAS- and BRAF-mutant colorectal cancer cell lines. This genotype selectivity was mediated by suppression of the antiapoptotic protein MCL-1 and disruption of BIM–MCL-1 complexes in response to TORC1/2 inhibition, which sensitized KRAS-mutant cells to ABT-263 and triggered apoptosis. Furthermore, dual treatment with ABT-263 and AZD8055 preferentially induced tumor regression in KRAS-mutant colorectal cancer xenograft and genetically engineered mouse models. These results support further clinical development of this therapeutic combination for patients with KRAS- and BRAF-mutant colorectal cancer. For details, please see the article by Faber and colleagues on page 42.